This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Mucolipidosis type II / III (I-cell disease / pseudo-Hurler polydystrophy)Mucolipidosis Type II / III (I-Cell Disease / Pseudo-Hurler Polydystrophy)

Basic classification information
ICD-10E77.0
Special Copayment Reduction codeV117
Main Korean nameMucolipidosis type II / III
SynonymsMucolipidosis II [I-cell disease], mucolipidosis III [pseudo-Hurler polydystrophy], defect in post-translational modification of lysosomal enzymes, ML II, ML III, I-cell disease, Pseudo-Hurler polydystrophy

Contents

1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Mucolipidosis type II (ML II), i.e., I-cell disease, was first described in 1967 by Leroy and DeMars. They observed peculiar cells filled with granular inclusion bodies under light microscopy in cultured fibroblasts from patients and named them 'I-cell' after the abbreviation of 'inclusion cell'. Subsequent research revealed that these inclusion bodies are distended lysosomes composed of undegraded lysosomal substrates.

Mucolipidosis type III (ML III), i.e., pseudo-Hurler polydystrophy, was first described in 1966 by Maroteaux and Lamy. Although its clinical picture resembles MPS I (Hurler syndrome), urinary GAG excretion is normal, so it was recognized as a separate disease. The biochemical link between ML II and ML III was elucidated in the early 1970s by Hickman and Neufeld, who identified the common defect in both diseases that lysosomal enzymes fail to reach the intracellular lysosomes and are secreted extracellularly.

Mutations in the GNPTAB gene, which encodes the alpha and beta subunits of UDP-N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase), the common molecular cause of both diseases, were finally confirmed in 2006 by Bao et al.

2. Causes

ML II and ML III result from a defect in the post-translational modification of lysosomal enzymes. For lysosomal enzymes to be correctly targeted to lysosomes, a recognition marker called mannose-6-phosphate (M6P) must be attached to the enzyme. The enzyme that catalyzes the first step of the reaction attaching this marker is GlcNAc-1-phosphotransferase (UDP-GlcNAc:lysosomal enzyme GlcNAc-1-phosphotransferase).

This enzyme is composed of alpha and beta subunits (encoded by the GNPTAB gene) and a gamma subunit (encoded by the GNPTG gene). When phosphotransferase activity is completely lost due to null mutations of the GNPTAB gene, ML II (I-cell disease) develops, and variants that retain some residual enzyme activity cause ML IIIalpha/beta (pseudo-Hurler polydystrophy). Mutations of the GNPTG gene cause ML IIIgamma, which is clinically similar to ML IIIalpha/beta but generally has a milder course.

3. Genetics

The GNPTAB gene is located on chromosome 12q23.3 and contains 21 exons. Various pathogenic variants causing ML II and ML IIIalpha/beta have been reported. In ML II, variants that completely abolish enzyme activity, such as frameshift and nonsense mutations, predominate, whereas in ML IIIalpha/beta, missense mutations that retain residual activity are more common. The GNPTG gene is located on chromosome 16p13.3, and mutations of this gene cause ML IIIgamma.

All types are inherited in an autosomal recessive manner. The sibling recurrence risk is 25%. A phenotype-genotype correlation generally exists between the presence of null mutations and phenotypic severity, but complete prediction is difficult. Molecular genetic testing can distinguish ML II and ML III genotypes, which helps prognostic counseling. Prenatal diagnosis is possible by measuring enzyme activity or molecular analysis in fibroblasts after CVS or amniocentesis.

4. General epidemiology

ML II and ML III are very rare diseases. The incidence of ML II is estimated at about 1 per 300,000–600,000 births. The incidence of ML III is reported to be somewhat lower than or similar to that of ML II. Clustering due to a founder effect has been reported in some regions, and the incidence of ML II and ML III is known to be relatively high in the Quebec region of Canada.

There is no sex difference; ML II is often diagnosed early because symptoms appear from the neonatal period or early infancy. In ML III, symptoms appear gradually in late early childhood (after age 2–4), so diagnosis tends to be later. Both diseases are so rare that only a few hundred cases have been reported worldwide.

5. Pathophysiology

Normally, in the Golgi apparatus, GlcNAc-1-phosphotransferase adds GlcNAc-1-phosphate to mannose residues of lysosomal hydrolases, and the GlcNAc residue is subsequently removed to form the mannose-6-phosphate (M6P) marker. This M6P marker binds M6P receptors distributed on the cell surface and in the Golgi apparatus, directing the enzymes to be targeted into lysosomes.

In ML II/III, the M6P marker is not formed due to GlcNAc-1-phosphotransferase deficiency, so lysosomal enzymes cannot move to lysosomes and are secreted extracellularly. Intracellular lysosomes lack functional hydrolases, so various substrates such as GAGs, glycolipids, and glycoproteins accumulate within lysosomes. A paradoxical biochemical feature appears in which the activities of several lysosomal enzymes are markedly increased in serum while intracellular enzyme activities are reduced.

The clinical differences between ML II and ML III arise from the degree of residual phosphotransferase activity. In ML II, activity is completely lost, causing severe multiorgan involvement from the neonatal period, whereas in ML IIIalpha/beta residual activity remains, resulting in later onset and slower progression.

6. Symptoms

ML II (I-cell disease)

Symptoms appear from the neonatal period. At birth or in the early neonatal period, skeletal abnormalities (congenital hip dislocation, limb deformities), distinctive facial features, severe hypotonia, and growth retardation are observed. In infancy, severe psychomotor developmental delay becomes evident, and most never begin to walk. Recurrent respiratory infections, cardiac valve insufficiency, hepatosplenomegaly, and hernias are also common. The disease progresses rapidly, and most die before age 10.

ML III (pseudo-Hurler polydystrophy)

Symptoms usually begin at age 2–4. The most common initial symptoms are joint stiffness and pain, prominent in the hand, wrist, and shoulder joints. Spinal cord compression symptoms (weakness, impaired coordination) due to cervical spine instability are an important complication. Growth retardation, mild to moderate distinctive facial features, corneal clouding, and cardiac valve abnormalities also appear. Intellectual disability may be milder than in ML II or absent, but mild to moderate intellectual disability is reported in about 50% of patients.

7. Signs

Skeletal system

Dysostosis multiplex appears severely in ML II and mildly to moderately in ML III. Limited joint range of motion is the most characteristic early sign of ML III, with flexion contractures of the shoulder, hand, and hip joints being especially prominent. Scoliosis, kyphosis, hip dysplasia, and osteoporosis are also observed. Cervical spine instability in ML III patients is a potentially life-threatening complication, so regular cervical spine MRI monitoring is essential.

Facial and ophthalmologic

Coarse facies appear in both types and are more prominent in ML II. Corneal clouding is common and is often confirmed on slit-lamp examination even in ML III. Decreased vision and retinal degeneration may also accompany it.

Cardiac

Cardiac valve thickening and insufficiency (especially the mitral and aortic valves) are an important cause of morbidity. Cardiomyopathy may also accompany ML II. Regular echocardiographic follow-up is needed.

Blood test findings

A marked increase in the activity of many lysosomal enzymes in serum (beta-hexosaminidase, iduronidase, arylsulfatase A/B, etc.) is the characteristic biochemical finding of both types. This is an important clue for diagnosis.

8. Screening

Newborn screening programs for ML II/III have not yet been standardized. The possibility of DBS-based screening using the characteristic marked increase in multiple lysosomal enzyme activities in serum or plasma is being studied, but actual clinical application is still at the research stage.

A first-line screening test that can be performed when clinically suspected is measurement of multiple lysosomal enzyme activities in serum. In ML II/III patients, the activities of several lysosomal enzymes in serum, such as beta-hexosaminidase, alpha-mannosidase, and iduronidase, are increased to dozens of times normal or more. This test can be performed as a simple blood test with results obtained relatively quickly, making it a useful initial screening tool when clinically suspected.

ML II is often already suspected in the neonatal period because of severe joint contractures and skeletal abnormalities, and ML III is often referred to pediatricians or pediatric rheumatologists for joint stiffness and growth retardation, so raising disease awareness among these specialists is important for shortening diagnostic delay.

9. Diagnosis

Confirmation is made by demonstrating markedly reduced GlcNAc-1-phosphotransferase activity in fibroblasts or leukocytes and confirming the characteristic biochemical pattern of increased activity of many lysosomal enzymes in serum. Confirmation by molecular genetic testing is recommended.

Biochemical tests

Molecular genetic testing

Identification of pathogenic variants by sequencing of the GNPTAB (ML II, ML IIIalpha/beta) or GNPTG (ML IIIgamma) gene. Efficient diagnosis is possible with an NGS-based lysosomal storage disease panel.

Imaging and other

10. Treatment

There is currently no specific approved therapy for ML II/III. Treatment centers on supportive care for each symptom.

Multidisciplinary supportive care

Treatments under investigation

Gene therapy and strategies to improve enzyme targeting are at the research stage. Hematopoietic stem cell transplantation (HSCT) has been performed in ML II patients in some studies, but given the severe neonatal phenotype and transplant-related morbidity and mortality, the evidence is currently insufficient. Bisphosphonates are sometimes used to manage osteoporosis and bone pain.

11. Prognosis

The prognosis of ML II is poor. Most patients die before age 10, in many cases at age 5–8, from cardiopulmonary failure or recurrent respiratory infections. Neurological development is severely delayed from the outset, and achieving motor milestones such as walking is very rare. Patients are vulnerable to acute deterioration from high fever, systemic infection, and surgical complications.

The prognosis of ML III is markedly better than that of ML II. Many patients survive into adulthood, and survival beyond the 30s–40s has been reported. However, progressive decline in joint function, cervical spine instability, cardiac valve disease, and decreased vision gradually worsen, increasing physical disability. Regarding cognitive function, about half of patients show mild to moderate intellectual disability, and some can attend regular school. Ongoing multidisciplinary management to maintain quality of life is essential.

12. Prevention

ML II/III is autosomal recessive, and primary prevention is based on genetic counseling and prenatal diagnosis. The sibling recurrence risk is 25%, and prevention is possible through carrier testing and prenatal diagnosis (enzyme activity or molecular analysis after CVS or amniocentesis). Preimplantation genetic testing (PGT-M) is also an option.

In ML II, skeletal abnormalities (shortened limbs, bone deformities) found on prenatal ultrasound sometimes prompt the diagnosis. Because prenatal diagnosis of ML III is difficult, when there is a family history it is essential to identify the familial variant in advance by molecular genetic testing. Complication prevention and functional preservation are possible through multidisciplinary management after early diagnosis, and early monitoring for cervical spine instability is an important secondary prevention strategy.

13. References

  1. Leroy JG, DeMars RI. Mutant enzymatic and cytological phenotypes in cultured human fibroblasts. Science. 1967;157(3790):804-806. PMID: 6036538
  2. Bao M, Elmendorf BJ, Booth JL, et al. Bovine UDP-N-acetylglucosamine: lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase. II. Enzymatic characterization and identification of the catalytic subunit. J Biol Chem. 1996;271(49):31446-31451. PMID: 8940157
  3. Tiede S, Storch S, Lubke T, et al. Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Med. 2005;11(10):1109-1112. PMID: 16200072
  4. Cathey SS, Leroy JG, Wood T, et al. Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet. 2010;47(1):38-48. PMID: 19617638
  5. Leroy JG, Cathey SS, Friez MJ. Mucolipidosis II. In: Adam MP, et al., editors. GeneReviews. Seattle (WA): University of Washington; 2008. PMID: 20301394
  6. Otomo T, Muramatsu T, Yorifuji T, et al. Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. J Hum Genet. 2009;54(3):145-151. PMID: 19197271
  7. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J. 1987;1(6):462-468. PMID: 3315809
  8. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589-604. PMID: 21637572
  9. Ficicioglu C, Mandell J, Sharer J, et al. Mucolipidosis type II (I-cell disease) presenting as a skeletal dysplasia in the neonatal period. J Inherit Metab Dis. 2004;27(1):107-110. PMID: 15038582
  10. Spranger J, Gehler J, Cantz M. Mucolipidosis I--a sialidosis. Am J Med Genet. 1977;1(1):21-29. PMID: 612123